Anika TherapeuticsANIK -2.40%58 Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus rates ANIK with a GF Score™ of 58/100 and a GF Value™ of $20.54 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 504 Drug Manufacturers companies, Anika Therapeutics ranks worse than 198412.5% on this metric.
As of today (2026-07-01), the Forward Annual Dividend Yield of Anika Therapeutics is 0.00%.
As of today (2026-07-01), the Trailing Annual Dividend Yield of Anika Therapeutics is 0.00%.
ANIK's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.08 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Anika Therapeutics Forward Dividend Yield % Related Terms
ANIK vs LFCR, DERM, ASRT: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Anika Therapeutics (ANIK) has a Forward Dividend Yield % of 0.00% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Anika Therapeutics and its competitors. According to the industry distribution chart, Anika Therapeutics ranks #999999 out of 504 companies in the Drug Manufacturers industry.
Is Anika Therapeutics' Forward Dividend Yield % too high?
Anika Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Anika Therapeutics ranks #999999 out of 504 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anika Therapeutics has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Forward Dividend Yield % compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #999999 out of 504 companies for Forward Dividend Yield %. This places Anika Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 2.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.08, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.54, compared to a current price of $14.63 — trading 28.8% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Anika Therapeutics' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (ANIK) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of $14.63 is trading 28.8% below its estimated GF Value™ of $20.54.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for ANIK:
Forward Dividend Yield %: 0.00%
GF Value™: $20.54 vs. price of $14.63 (28.8% below fair value)
No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
58GF Score
Get the complete analysis for ANIK
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIK has been successfully added to your 